Financing

Payment for contingent consideration liability (financing)

Zimmer Biomet Holdings Payment for contingent consideration liability (financing) increased by 807.9% to $69.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 296.6%, from $17.40M to $69.00M. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2017
Last reportedQ1 2026May 1, 2026

How to read this metric

An increase indicates that acquired businesses are hitting performance targets, which may lead to future growth but requires immediate cash outflows.

Detailed definition

This metric represents cash payments made to settle liabilities related to earn-outs or performance-based milestones fro...

Peer comparison

Specific to companies with active M&A strategies; peers in the semiconductor industry often report these as part of acquisition-related financing activities.

Metric ID: abbv_payment_contingent_consideration_financing

Historical Data

10 periods
 Q2 '21Q3 '21Q4 '21Q1 '23Q2 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26
Value$700.00K$0.00$2.40M$9.60M$700.00K$1.50M$2.00M$17.40M$7.60M$69.00M
QoQ Change-100.0%+300.0%-92.7%+114.3%+33.3%+770.0%-56.3%+807.9%
YoY Change-84.4%>999%+280.0%+296.6%
Range$0.00$69.00M
CAGR+669.3%
Avg YoY Growth+388.0%
Median YoY Growth+288.3%

Frequently Asked Questions

What is Zimmer Biomet Holdings's payment for contingent consideration liability (financing)?
Zimmer Biomet Holdings (ZBH) reported payment for contingent consideration liability (financing) of $69.00M in Q1 2026.
How has Zimmer Biomet Holdings's payment for contingent consideration liability (financing) changed year-over-year?
Zimmer Biomet Holdings's payment for contingent consideration liability (financing) increased by 296.6% year-over-year, from $17.40M to $69.00M.
What does payment for contingent consideration liability (financing) mean?
Cash paid to settle acquisition-related performance milestones.